Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor

Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor

Abstract Introduction The triple-combination (TC) cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimen elexacaftor, tezacaftor, and ivacaftor was shown to be safe and efficacious in phase 3 trials of people with cystic fibrosis (pwCF) ≥ 12 years of age with ≥ 1 F508del-CFTR a...

Full description

Bibliographic Details
Main Authors: Alice Tsai, Shu-Pei Wu, Eric Haseltine, Sanjeev Kumar, Samuel M. Moskowitz, Paul Panorchan, Kushal Shah
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-07-01
Series:Pulmonary Therapy
Subjects:
CFTR modulator
Cystic fibrosis
Elexacaftor
Ivacaftor
Lumacaftor
Physiologically based pharmacokinetic modeling
Online Access:https://doi.org/10.1007/s41030-020-00124-7

Internet

https://doi.org/10.1007/s41030-020-00124-7

Similar Items